

CURRICULUM VITAE

Name: Barry Stephen Taylor

Position: Associate Director
Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Memorial Sloan Kettering Cancer Center

Assistant Member and Josie Robertson Investigator
Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center

Assistant Attending
Department of Epidemiology and Biostatistics
Memorial Sloan Kettering Cancer Center

Address: Memorial Sloan Kettering Cancer Center
1275 York Avenue, Box 20
New York, NY 10065
Voice: (646) 888-3726
Fax: (646) 888-3266
Email: taylorb@mskcc.org
Web: <http://www.mskcc.org/research/lab/barry-taylor>

EDUCATION

1999 B.S. Cognitive Science; University of California, San Diego
2006 M.S. Bioinformatics; University of Michigan
2009 Ph.D. Physiology, Biophysics, and Systems Biology; Weill Medical College of Cornell University (Chris Sander, Thesis Supervisor)

PREVIOUS PROFESSIONAL EXPERIENCE

1998-99 Research Assistant; University of California, San Diego
2004-06 Graduate Student Research Assistant; University of Michigan Medical School
2006-09 Graduate Research Staff; Weill Medical College of Cornell University
2009-12 Cancer Genomics Research Coordinator; Memorial Sloan Kettering Cancer Center
2009-12 David H. Koch Fellow; Memorial Sloan Kettering Cancer Center
2010-12 Visiting Scientist; University of California, San Francisco (UCSF)
2012-14 Assistant Professor, Department of Epidemiology and Biostatistics, UCSF
Assistant Professor, Department of Medicine, UCSF
2012-14 Member; California Institute for Quantitative Biosciences, UCSF
Member; Helen Diller Family Comprehensive Cancer Center, UCSF

HONORS AND AWARDS

2008 Geoffrey Beene Graduate Fellowship, Memorial Sloan Kettering Cancer Center
2008 Second Place Award, \$10K Genome Grant Program, Life Technologies
2009 Young Investigator Award, Connective Tissue Oncology Society (CTOS)
2011 Young Investigator Award, Prostate Cancer Foundation (PCF)

2013 Brain Tumor SPORE Career Development Award (UCSF)
2013 Marc A. Shuman Mentoring in Hematology/Oncology Award, Nominated
2013 Sontag Foundation Distinguished Scientist Award
2014 Incumbent, Josie Robertson Investigator, Memorial Sloan Kettering Cancer Center
2015 American Cancer Society, Research Scholar Award

ACADEMIC SERVICE

a) National Advisory

2013- Member, Prostate Cancer Foundation (PCF) Research Award Review Committee
2013 Member, AACR Clinical and Translational Cancer Research Grants Scientific Review Committee
2013 Member, Melanoma Research Alliance (MRA)-Hidary Acral Melanoma Genomics Team Science Award Scientific Review Committee
2013-15 Member, AACR Gertrude B. Elion Cancer Research Award Scientific Review Committee
2014-15 Member, Planning Committee for the PCF Stupski Prize in Precision Oncology
2015- Member, New York Genome Center Scientific and Clinical Steering Committee
2015- Member, CPRIT Clinical and Translational Cancer Research Scientific Peer Review Panel
2015- Member, External Advisory Board, Weill Cornell SPORE in Prostate Cancer
2015- Member, AACR GENIE initiative
2016 Member, NIH ZRG1 BMCT-C(01) Molecular Targets and Cancer Intervention Study Section

b) Institutional

2010-11 Member, Informal Working Group on Clinical Sequencing, UCSF
2012-14 Member, Working group on Genomic Medicine (Chair: R. Nussbaum), UCSF
2012-14 Member, Graduate Programs in Biomedical Sciences (BMS) and Biological and Medical Informatics (BMI), UCSF
2013-14 Lead, Genomic Medicine Initiative – Informatics, UCSF
2013-14 Member, Precision Medicine in Oncology Executive Committee, UCSF
2015 Member, Review Committee for Cycle for Survival, MSKCC
2015- Member, Review Committee for the Geoffrey Beene Cancer Research Center and Center for Metastasis Research, MSKCC
2015- Member, High Performance Computing Oversight Committee
2015- Member, Search Committee for Chair of Computational Biology (Sloan Kettering Institute)
2016- Member, Tri-Institutional Computational Biology & Medicine Curriculum Committee

c) Public Service

2003-04 New York University Downtown Hospital, Emergency Room Direct Patient Care
2004-05 University of Michigan, Rackham Graduate Student Forum, Representative
2005 13th Intelligent Systems for Molecular Biology (ISMB) Conference Volunteer

d) Memberships

2004-06 American Society for Mass Spectrometry
2004- American Association for the Advancement of Science
2006-09 New York Academy of Sciences
2007- American Association for Cancer Research

INVITED SEMINARS AND LECTURES

a) International

2013 Invited Speaker, Banff International Research Station (BIRS)

- 2016 Invited speaker, 10th International Workshop on Pharmacodynamics and Anticancer Agents
 2017 Invited Speaker, Nikolas Symposium, Athens, Greece.

b) National

- 2010 Invited speaker, American Association for Cancer Research (AACR)
 2012 Plenary session, AACR Advances in Prostate Cancer Research
 2012 Invited speaker, MMHCC Symposium on Mouse Models of Prostate Cancer
 2012 Invited speaker, CSHL Personal Genomes and Medical Genomics
 2013 Invited speaker, 20th Annual Prostate Cancer Foundation Scientific Retreat
 2013 Invited speaker, Molecular Medicine Tri-Conference, Cambridge Healthtech Institute
 2014 Invited keynote, NIH/NCI Center of Excellence in Integrative Cancer Biology Mini-symposium
 2014 Invited speaker, Five Points Lecture Series, New York Genome Center
 2015 Invited speaker, AACR Integrating Clinical Genomics and Therapy
 2016 Session Chair, Educational Session, AACR Annual Meeting
 2016 Session Chair, Minisymposium, AACR Annual Meeting

c) Regional and Other Invited Presentations

- 2007 Cancer Genome Analysis Group, Broad Institute of MIT and Harvard
 2007 Allied Program in Biochemistry, Cell, and Molecular Biology; Weill Medical College of Cornell University
 2008 Biostatistics Seminar Series, Memorial Sloan-Kettering Cancer Center
 2010 Urologic Oncology Program, University of California, San Francisco
 2011 Seminars in Computational and Systems Biomedicine, Weill Medical College of Cornell University
 2011 Statistics and Genomics Seminar, University of California, Berkeley
 2011 Cancer Genetics Program Retreat, University of California, San Francisco
 2012 Blueprint Medicines, Cambridge MA.
 2012 Bioinformatics and Computational Biology Seminars, MD Anderson Cancer Center
 2012 California Institute of Quantitative Biosciences, Cancer Club
 2012 Center for Cancer Systems Biology Symposium, Memorial Sloan-Kettering Cancer Center
 2012 Cancer Epidemiology Seminar Series, University of California, San Francisco
 2013 Accelerate Brain Cancer Cures: Low Grade Glioma Research Workshop
 2013 New York Bioinformatics User Group Meeting, Simons Foundation
 2013 Millennium Pharmaceuticals, Inc. Translational Medicine Speaker's Series
 2013 Cancer Genetics Program Meeting, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
 2013 Annual Prostate Cancer Retreat Research Retreat, University of California, San Francisco
 2013 Biomedical Sciences Program Retreat, University of California, San Francisco
 2014 Board of Scientific Consultants, Memorial Sloan Kettering Cancer Center
 2015 Center for Mechanism-based Therapies, Memorial Sloan Kettering Cancer Center
 2015 The Sontag Foundation Mid-Winter Retreat, Florida
 2015 Geoffrey Beene Center Annual Retreat, Memorial Sloan Kettering Cancer Center
 2015 Urological Oncology Centennial Conference, Memorial Sloan Kettering Cancer Center
 2015 Cancer Genomics Research Network Meeting, New York Genome Center
 2016 The Sontag Foundation Mid-Winter Retreat, Arizona

TEACHING EXPERIENCE

- 1999 Teaching Assistant, Cognitive Engineering
 Department of Cognitive Science, University of California, San Diego

- 1999 Teaching Assistant, Systems Neurobiology
Department of Cognitive Science, University of California, San Diego
- 2010 Lecturer, Cancer Genomics Data Analysis, Evolutionary Systems Biology of Cancer
Weill Medical College of Cornell University
- 2010 Lecturer, Oncogenomics; Core Course in Cancer Biology
Gerstner Sloan Kettering Graduate School of Biomedical Sciences
- 2010-13 Lecturer, BMI-219 Statistical Methods for Array and Sequence Data
Biological and Medical Informatics Graduate Program, UCSF
- 2012-13 Lecturer, BMS-203 Advanced Topics in Cancer Research
Biomedical Sciences Graduate Program, UCSF
- 2013 Lecturer, Cancer Biology Didactics for Radiation Oncology Residents
Department of Medicine, UCSF
- 2013 Lecturer, Cancer Biology Didactics for Hematology and Oncology Fellows
Department of Medicine, UCSF
- 2013-14 Lecturer, BMS-230 Cell and Molecular Biology of Cancer
Biomedical Sciences Graduate Program, UCSF
- 2014- Lecturer, Core Course in Cancer Biology
Detecting Chromosomal Structural Rearrangements, and
Computational Biology Lab Exercise
Gerstner Sloan Kettering Graduate School of Biomedical Sciences

RESEARCH TRAINING

a) Postdoctoral and/or Clinical Fellows/Research Associates

- 2012-14 Saurabh Asthana, Ph.D. Research associate
- 2013-15 Oliver Zill, Ph.D. Awarded 2013 ACS Postdoctoral Fellowship
- 2013-15 Jocelyn Chapman, M.D. Gynecologic Oncology Fellow (UCSF/Stanford)
- 2014- Martin Kampmann, Ph.D. NIH/NCI K99-R00 Advisory Committee Member
- 2015- Alexander Penson, Ph.D. Research Associate
- 2015- Tripti Bhattarai Shrestha, Ph.D. Postdoctoral Fellow
- 2015- Phillip Jonsson, Ph.D. Postdoctoral Fellow

b) Doctoral Students

- 2012-14 Rachel Rosenthal, Ph.D. University of California, San Francisco
Current: Graduate Student, CR-UK London Research Institute (Advisor: C. Swanton)
- 2013- Matthew T. Chang, Pharm.D/Ph.D, University of California, San Francisco
- 2016- Alexander Gorelick, Ph.D. Tri-Institutional CBM program, Weill/Cornell

c) Masters

- 2013-14 Bushra Samad, M.S. Bioengineering, University of California, Berkeley/UCSF

d) Thesis and/or Qualifying/Exam Committees

- | | | |
|-------|---|-------------------------------|
| 2013 | Kamena Kostova, Biomedical Sciences, UCSF | Advisor: Jonathan Weissman |
| 2013 | James Webber, Biomedical Informatics, UCSF | Advisor: Sourav Bandyopadhyay |
| 2014 | Juliet Goldsmith, Biomedical Sciences, UCSF | Advisor: Jayanta Debnath |
| 2014- | Tali Mazor, Biomedical Sciences, UCSF | Advisor: Joseph Costello |

2014- Hannah Johnsen, Gerstner Sloan Kettering Advisor: David B. Solit

REVIEWER (ad hoc)

<i>Science</i>	<i>Proc. of the National Academy of Sciences</i>
<i>Nature Medicine</i>	<i>Clinical Cancer Research</i>
<i>Nature Biotechnology</i>	<i>PLoS Genetics</i>
<i>Nature Scientific Reports</i>	<i>PLoS Computational Biology</i>
<i>Cancer Discovery</i>	<i>PLoS ONE</i>
<i>Bioinformatics</i>	<i>Elsevier Book Review</i>
<i>Cancer Research</i>	<i>Human Genetics</i>
<i>Journal of Clinical Investigation</i>	<i>European Urology</i>
<i>Cancer Cell</i>	

RESEARCH AWARDS AND GRANTS

a) Active

GC202595 Prostate Cancer Foundation Outcome prediction from the pattern of aberrations in prostate cancer genomes Role: Principal Investigator	(PI, Taylor)	NCE \$225,000
1 R01CA169316-01 NIH/NCI Imaging-guided genomics of malignant transformation Role: Co-investigator	(PI, Costello)	04/01/13 – 03/31/18 \$307,509/yr
1 R01CA180037-01 NIH/NCI (PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood Cancers Role: Co-investigator	(PI, Shannon)	07/01/13- 06/30/17 \$250,000/yr
GC223715 Sontag Foundation Distinguished Scientist Award Explores the clonal origins and therapeutic targeting of recurrent gliomas Role: Principal Investigator	(PI, Taylor)	10/01/13 – 09/30/17 \$150,000/yr
No Number Cycle for Survival On the evolutionary origins of metastatic bladder cancers Role: Principal Investigator	(PI, Taylor)	09/01/14 – 08/31/16 \$160,000/yr
127350-RSG-15-067-01-TBG ACS Research Scholar Award Dissecting the translational control of cancer progression Role: Principal Investigator	(PI, Taylor)	07/01/15-06/30/19 \$165,000/yr
1 U54 OD020355-01 NIH/NCI MSKCC Pilot Center for Precision Disease Modeling	(PI: Lowe/Taylor)	08/01/15 - 06/30/20 \$1,135,056/yr

Coordinates and enhances the institution's genomic, computational, and animal modeling efforts to facilitate the development of biologically accurate models of human disease.

Role: Principal Investigator, Bioinformatics Core

No Number (Co-PI, Taylor and Solit) 01/01/16-12/31/16
Experimental Therapeutics Center (MSKCC) \$150,000/yr
Development of therapeutic strategies that change the natural history of tumors with mutant Ras
Role: Co-principal Investigator

b) Pending

1 R01 CA207244-01 (PI: Taylor)
NIH/NCI
Targeting AKT-Mutant Human Cancers
Establish the determinants of sensitivity and resistance to AKT inhibitors in diverse solid cancers
Role: Principal Investigator

1 R01 CA204749-01A1 (PI: Taylor)
NIH/NCI
Understanding Long Tail Driver Mutations in Cancer
Computationally prioritize, experimentally validate, and clinically cross-validate long tail driver mutations in patients with lethal cancer
Role: Principle Investigator

2 P50 CA092629-16 (PI: Scher/Taylor)
NIH/NCI
SPORE in Prostate Cancer
RP-1: Understanding the Molecular Evolution of Castrate-Resistant Prostate Cancer
The translational research projects in this program aim to use knowledge of animal and human prostate cancer biology to develop and test interventions related to the prevention, early detection, diagnosis, prognosis, and treatment of prostate cancer in men.
Role: Principal Investigator

1 U24 CA213274-01 (PI: Rudin)
NIH/NCI
Coordinating center for the NCI small cell lung cancer research consortium
This Coordinating Center will promote information exchange and resource sharing among investigators in the NCI-supported Small Cell Lung Cancer Consortium, with the ultimate goal of reducing the impact of this disease by facilitating prevention, early detection, and novel therapeutic research.
Role: Co-Investigator

c) Past

3 P50CA097257 10S1 (PI, Berger) 07/01/13 – 06/31/14
NIH/NCI \$45,000/yr
UCSF Brain Tumor SPORE
Career Development Research Program (CDRP)
Role: Principal Investigator

1 U24CA143840-01 (PI, Sander) 09/28/09 – 07/31/14
NIH/NCI \$1,540,730/yr
MSKCC Center for Translational Cancer Genomic Analysis

Genome Data Analysis Center type B (GDAC-B) – The Cancer Genome Atlas (TCGA)

Role: Co-Investigator (*sub-contract*)

P30 CA008748

(PI, Thompson)

07/23/14 – 12/31/14

NIH/NCI

\$200,000

MSKCC Cancer Center Support Grant

Developmental Funds

Role: Principal Investigator

PEER REVIEWED PUBLICATIONS:

(* These authors contributed equally to this work)

(†Co-corresponding authors)

1. **Taylor BS**, Varambally S, Chinnaiyan AM. A systems approach to model metastatic progression. *Cancer Res.* 2006; 66(11): 5537-9
2. **Taylor BS**, Varambally S, Chinnaiyan AM. Differential proteomic alterations between localized and metastatic prostate cancer. *Br J Cancer.* 2006; 95(4): 425-430
3. Mathew JP, **Taylor BS**, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B. From bytes to bedside: data integration and computational biology for translational cancer research. *PLoS Comput Biol.* 2007; 3(2): e12
4. **Taylor BS**, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, Menon A, Wei JT, Nesvizhskii AI, Ghosh D, Omenn GM, Lubman DM, Chinnaiyan AM, Sreekumar A. Humoral response profiling reveals pathways to prostate cancer progression. *Mol Cell Proteomics*, 2008; 7(3): 600-11
5. Cancer Genome Atlas Research Network; Brennan C, Socci ND, Olshen A, **Taylor BS**, Lash A, Schultz N, Reva B, Antipin Y, Stukalov A, Gross B, Cerami E, Wang W, Qin L, Seshan VE, Villafania L, Cavatore M, Borsu L, Viale A, Gerald W, Sander C, Ladanyi M. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature.* 2008; 455(7216): 1061-8
6. **Taylor BS**, Barretina J, Socci ND, DeCarolis P, Ladanyi M, Meyerson M, Singer S, Sander C. Functional copy-number alterations in cancer. *PLoS ONE.* 2008; 3(9): e3179
7. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, **Taylor BS**, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit B. Genetic predictors of MEK-dependence in non-small cell lung cancer. *Cancer Res.* 2008; 68(22): 9375-83
8. Pratilas CA, **Taylor BS**, Ye Q, Viale A, Sander C, Solit DB, Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. *Proc Natl Acad Sci.* 2009; 106(11): 4519-24
9. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, **Taylor BS**, Sander C, Couto SS, Gerald WL, Sawyers CL. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. *Nature Genetics.* 2009; 41(5): 524-526
10. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chlmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, **Taylor**

B, Schultz N, Major J, Heguy A, Fang F, Mellinshoff IK, Chan TA. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. *Proc Natl Acad Sci*. 2009; 106(23): 9435-40

11. Chitale D*, Gong Y*, **Taylor BS***, Broderick S*, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman M, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M. An integrated genomic analysis of lung cancer reveals loss of *DUSP4* in *EGFR*-mutant tumors. *Oncogene*. 2009; 28(31): 2773-2783
12. Veeriah S*, **Taylor BS***, Meng S*, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinshoff IK, Solit DB, Chan TA. Somatic mutations of the Parkinson's disease-associated gene *PARK2* in glioblastoma and other human malignancies. *Nature Genetics*. 2010; 42(1): 77-82
13. Berger AH, Niki M, Morotti A, **Taylor BS**, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Feldstein-Teruya J, Gerald WL, Ladanyi M, Pandolfi PP. Identification of *DOK* genes as lung tumor suppressors. *Nature Genetics*. 2010; 42(3): 216-223
14. Cerami E, Demir E, Schultz N, **Taylor BS**, Sander C. Automated network analysis identifies core pathways in glioblastoma. *PLoS ONE*. 2010; 5(2): e8918
15. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, **Taylor BS**, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD. Transcriptional pathway signatures predict MEK addition and response to selumetinib AZD6244. *Cancer Res*. 2010; 70(6): 2264-73
16. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, **Taylor BS**, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte-Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. *Cancer Res*. 2010; 70(14): 5901-11
17. **Taylor BS***, Schultz N*, Hieronymus H*, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. *Cancer Cell*. 2010; 18(1): 11-22.
18. Barretina J*, **Taylor BS***, Ramos AH, Lagos-Quintana M, Banerji S, DeCarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel C, Getz G, Antipin Y, Beroukhir R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell T, Cibulskis K, Onofrio RC, Saito T, Shukla NN, Lau C, Nelander S, Silver S, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root D, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, and Singer S. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy. *Nature Genetics*. 2010; 42(8): 715-21
19. Joseph EW, Pratilas CA, Poulidakos PI, Tadi M, Wang W, **Taylor BS**, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. *Proc Natl Acad Sci*. 2010; 107(33): 14903-14908

20. Brill E, Goggle R, Angeles C, Lagos-Quintana M, Crago A, Laxa B, DeCarolis P, Zhang L, Antonescu A, Socci ND, **Taylor BS**, Sander C, Koff A, Singer S. Zic1 over-expression is oncogenic in liposarcoma. *Cancer Res.* 2010; 70(17): 6891-6901
21. **Taylor BS**, Ladanyi M. Clinical cancer genomics: how soon is now. *J. Pathol.* 2011; 223(2): 319-27
22. Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, **Taylor BS**, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL. MYC cooperates with AKT in prostate tumorigenesis and alters the sensitivity to mTOR inhibitors. *PLoS ONE.* 2011; 6(3): e17449
23. Bott M, Brevet M, **Taylor BS**, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen AB, Rusch V, Ladanyi M. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. *Nature Genetics*, 2011; 43(7): 668-72
24. Ugras S, Brill E, Jacobsen A, Hafner M, Socci ND, DeCarolis PL, Khanin R, O'Conner R, Mihailovic A, **Taylor BS**, Sheridan R, Viale A, Crago A, Antonescu CR, Sander C, Tuschl T, Singer S. Small RNA sequencing and functional characterization reveals microRNA-143 tumor suppressor activity in liposarcoma. *Cancer Res*, 2011; 71: 5659-69
25. Cancer Genome Atlas Research Network; Schultz N, Cerami E, **Taylor BS**, Socci ND, Olshen A, Reva B, Antipin Y, Shen R, Mankoo P, Sheridan R, Ciriello G, Chang WK, Bernanke JA, Lash A, Brennan C, Viale A, Levine DA, Ladanyi M, Sander C. Integrated genomic analyses of ovarian carcinoma. *Nature*, 2011; 474(7535): 609-15
26. **Taylor BS**, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. *Nat Rev Cancer*, 2011; 11: 541-557
27. Chen M, Pratt CP, Zeeman ME, Schultz N, **Taylor BS**, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC. Identification of PHLPP as a tumor suppressor reveals the role of feedback activation in *PTEN*-mutant prostate cancer progression. *Cancer Cell*, 2011; 20(2): 173-186
28. Morris LGT, **Taylor BS**, Bivona TG, Gong Y, Eng S, Banuchi VE, Brennan C, Kaufman A, Kasthuber ER, Singh B, Heguy A, Viale A, Mellinghoff I, Huse J, Ganly I, Chan TA. Genomic dissection of the EGFR/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. *Proc Natl Acad Sci.*, 2011; 108(47): 19024-19029
29. **Taylor BS**, DeCarolis PL, Angeles CV, Brenet F, Schultz N, Antonescu CR, Scandura JM, Sander C, Viale A, Socci ND, Singer S. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. *Cancer Discov*, 2011; 1(7): 587-597
30. Hanrahan AJ, Schultz N, Westfal ML, Sakr R, Giri D, Scaperi S, Janikariman M, Olvera N, She QB, Aghajanian C, King T, de Stanchina E, Spriggs D, Heguy A, **Taylor BS**, Sander C, Rosen N, Levine DA, Solit DB. Genetic determinants of AKT-dependence in serous ovarian cancer. *Cancer Discov*, 2012; 2(1): 56-67
31. Xing F, Persaud Y, Pratilas CA, **Taylor BS**, Janakiraman M, She Q-B, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit DB. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring ^{V600E}BRAF. *Oncogene*, 2012; 31(4): 446-457

32. Crago A, Socci ND, Decarolis PL, O'Connor R, **Taylor BS**, Qin LX, Antonescu CR, Singer S. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. *Clin Cancer Res*, 2012; 18(5): 1334-40
33. Cancer Genome Atlas Research Network; de Ronde JJ, Schultz N, Cerami N, Ciriello G, Goldberg AP, Gross B, Jacobsen A, Gao J, Kaczkowski B, Sinha R, Aksoy BA, Antipin Y, Reva B, Shen R, **Taylor BS**, Chan TA, Ladanyi M, Sander C. Comprehensive molecular characterization of human colon and rectal tumors. *Nature*. 2012; 487(7407): 330-337
34. Cancer Genome Atlas Research Network; Schultz N, Sinha R, Ciriello G, Cerami E, Gross B, Jacobsen A, Gao J, Arman Aksoy B, Weinhold N, Ramirez R, **Taylor BS**, Antipin Y, Reva B, Shen R, Mo Q, Seshan V, Ladanyi M, Paik PK, Sander C. Comprehensive genomic characterization of squamous cell lung cancers. *Nature*. 2012; 489(7417): 519-525
35. Cancer Genome Atlas Research Network; Ciriello G, Weinhold N, Schultz N, Gao J, Cerami E, Gross B, Jacobsen A, Sinha R, Arman Aksoy B, Antipin Y, Reva B, Shen R, **Taylor BS**, Ladanyi M, Sander C. Comprehensive molecular portraits of human breast tumors. *Nature*. 2012; 49(7418): 61-70
36. Tewari AK, Yardimci GG, Shibata Y, Sheffield NC, Song L, **Taylor BS**, Georgiev SG, Coetzee GA, Ohler U, Furey TS, Crawford GE, Febbo PG. Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. *Genome Biology*. 2012; 13:R88
37. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, **Taylor BS**[†], Solit DB[†]. Genome sequencing identifies a basis for everolimus sensitivity. *Science*. 2012; 338(6104): 221
38. Cancer Genome Atlas Research Network; Aksoy BA, Antipin Y, Ciriello G, Dresdner G, Gao J, Gross B, Jacobsen A, Ladanyi M, Reva B, Sander C, Sinha R, Sumer SO, **Taylor BS**, Cerami E, Weinhold N, Schultz N, Shen R. Integrated genomic characterization of endometrial carcinoma. *Nature*. 2013; 497(7447): 67-73
39. Cancer Genome Atlas Research Network; Jacobsen A, Brannon AR, Ciriello G, Schultz N, Hakimi AA, Reva B, Antipin Y, Gao J, Cerami E, Gross B, Aksoy BA, Sinha R, Weinhold N, Sumer SO, **Taylor BS**, Shen R, Ostrovnaya I, Hsieh JJ, Berger MF, Ladanyi M, Sander C. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*; 2013; 499(7456): 43-9
40. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaha I, Bala A, Kim P, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman I, Heguy A, Viale A, Bochner B, Reuter VE, Bajorin DF, Milowsky MI, **Taylor BS**, Solit DB. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. *J. Clin. Oncol.* 2013; 31(25): 3133-3140
41. **Cancer Genome Atlas Research Network**, Weinstein JN, Collisson EA, Mills GB, Mills Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The cancer genome atlas pan-cancer analysis project. *Nature Genetics*, 2013; 45(10): 1113-20
42. Olshen AB, Hsieh AC, Stumpf CR, Olshen RA, Ruggero D, **Taylor BS**. Assessing gene-level translational control from ribosome profiling. *Bioinformatics*, 2013; 29(23): 2995-3002

43. Stumpf CR, Olshen AB, Moreno MV, **Taylor BS****, Ruggero D**. The translational program of the mammalian cell cycle. *Mol. Cell*, 2013; 52(4): 574-582
44. Berger AH, Chen M, Morotti A, Jana JA, Niki M, Bronson RT, **Taylor BS**, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP. DOK2 inhibits EGFR-mutant lung adenocarcinoma. *PLoS ONE*, 2013; 8(11): e79526
45. Johnson BE, Mazor T, Hong C, Barnes M, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Aihara K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungal AJ, Jones SJM, Hirst M, Marra MA, Mukasa A, Saito N, Aburatani H, Berger MS, Chang SM, **Taylor BS****, Costello JF**. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science*, 2014; 343(6167): 189-93
46. Asmussen J, Tajon C, Oses-Prieto J, Lasater EA, **Taylor BS**, Burlingame A, Craik C, Shah NP. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addition. *Cancer Discov*. 2014; 4(2): 200-15
47. Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins M, Olivas V, Yan J, Pham L, Wang M, Bollag G, Solit DB, Collisson EA, Rudin CM, **Taylor BS**, Bivona TG. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. *Proc Natl Acad Sci*. 2014; 111(7): E748-57
48. Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, **Taylor BS**, Schultz N, Berger MF, Rosen N, Solit DB. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. *Cancer Res*. 2014; 74(8): 2340-50
49. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial carcinoma of the bladder. *Nature*, 2014; 507(7492); 315-322
50. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*, 2014; 511(7511); 543-550
51. Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang, MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel N, Murali R, Vickers A, Scardino PT, Sander C, Reuter VE, **Taylor BS***, Sawyers CL*. Copy number alteration burden predicts prostate cancer relapse. *Proc Natl Acad Sci*. 2014; 111(30): 11139-44
52. Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovskaya I, Kim P, Socci ND, Viale A, Schwartz GK, Reuter V, Bochner B, Rosenberg JE, Bajorin DF, Berger MF, Petrini JH**, Solit DB**, **Taylor BS****. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlie outlier response to cancer therapy. *Cancer Discov*. 2014; 4(9); 1014-1021
53. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; 513(7517); 202-209
54. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. *Cell* 2014; 159; 676-690

55. Carver BS, **Taylor BS**, Wanjala J, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL. MET amplification in advance stage murine and human prostate cancer. *Mol Cancer Ther* 2015; 14(1): 278-288
56. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015; 517(7536): 576-582
57. Van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, Malmstrom A, Hallbeck M, Heimans JJ, Kloezeman JJ, Stenmark-Askmal M, Lamfers MLM, Saito N, Aburatan H; Berger MS, Söderkvist P, **Taylor BS**, Molinaro AM, Wesseling P, Reijneveld JC, Chang SM, Ylstra B, Costello JF. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. *Acta Neuropathol* 2015; 129(4): 597-607
58. Cancer Genome Atlas Research Network. Genomic classification of cutaneous melanoma. *Cell* 2015; 161, 1681-1696
59. Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower grade gliomas. *N. Eng. J. Med.* 2015; 372(26): 2481-98
60. Chapman JS, Asthana S, Cade L, Chang MT, Wang Z, Zaloudek C, Ueda S, Collisson EA*, **Taylor BS***. Clinical sequencing contributes to a BRCA-associated cancer re-diagnosis that guides an effective therapeutic course. *J Natl Compr Canc Netw.* 2015; 13(7): 835-845
61. Garcia-Rendueles M. Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, **Taylor BS**, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giaccotti F, Ghossein R, Fagin JA. NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. *Cancer Discov.* 2015; 5(11): 1178-93
62. Mazor T, Pankov A, Johnson BE, Hong C, Bell RJA, Smirnov IV, Reis GF, Phillips JJ, Barnes M, Bollen AW, **Taylor BS**, Molinaro AM, Olshen AB, Song JS, Berger MS, Chang SM, Costello JF. Cell cycle signature and tumor phylogeny are encoded in the evolutionary dynamics of DNA methylation. *Cancer Cell*, 2015; 38(3): 307-17
63. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. *Cell*, 2015; 163(4): 1011-25
64. Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Choi J, Kim E, Cohen-Aubart F, Chun-Wei Lee S, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Héritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, **Taylor BS**, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O. Diverse and targetable kinase alterations drive histiocytic neoplasms. *Cancer Discov.* 2016; 6(2): 154-65
65. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao JJ, Socci ND, Solit DB, Olshen AB, Schultz N, **Taylor BS**. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. *Nature Biotechnol*, 2016; 34(2): 155-63
66. Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK, Desai NB, Zabor EC, Ostrovskaya I, Gopalan A, Chen Y, Fine SW, Tickoo SK, Gandhi A, Hreiki J, Viale A, Arcila ME, Dalbagni G, Rosenberg JE, Bochner BH, Bajorin DF, Berger MF, Reuter

- VE, **Taylor BS**, Solit DB. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. *Nat. Genet.* 2016; 48(4): 356-8. PMC4827439
67. Landa I, Ibrahimasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, **Taylor BS**, Ghossein R, Ganly I, Fagin JA. Characterization of the cancer genome of poorly differentiated and anaplastic thyroid cancers identifies distinct molecular hallmarks. *J Clin Invest*, 2016; 126(3): 1052-66
68. Rosenthal R, McGranahan N, Herrero J, **Taylor BS***, Swanton C*. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. *Genome Research*, 2016; 17: 31. PMC4762164
69. Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, Zhang JQ, Walczak EG, Kazmi MA, **Taylor BS**, Huber T, Chi P, Sakmar TP, Yu Chen Y. Recurrent activating mutations of G-protein coupled receptor CYSLTR2 in uveal melanoma. *Nat Genet*, 2016; 48(6): 675-680. PMID:27089179, PMC In Process.
70. Shukla N, Somwar R, Smith RS, Ambati SR, Munoz S, Merchant MS, D'Arcy P, Wang X, Kobos R, Antczak C, Binder B, Shum D, Radu C, Yang G, **Taylor BS**, Ng CK, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S, Djaballah H, Ladanyi M. Proteasome addiction defined in Ewings sarcoma is effectively targeted by a novel class of 19S proteasome inhibitors. *Cancer Research*, *In press*.
71. Yao Z, Yaeger R, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, **Taylor BS**, Rosen N. Tumors with class 3 BRAF mutants are RAS dependent and sensitive to its inhibition. *Submitted*
72. Ascierto ML, Moore-Makohon A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz G, Cottrell T, Kohutek ZA, Favarov A, Cope L, Hruban RH, Pardoll DM, Taylor BS, Solit DB, Iacobuzio-Donahue CA, Topalian SL. Phenotype switching as a mechanism of resistance to anti-PD-1 therapy. *Submitted*
73. Kim JH, Penson A, **Taylor BS**, Petrini JHJ. The Mre11-Nbs1 interface is essential for viability and tumor suppression. *Submitted*
74. Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spanoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, **Taylor BS**, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer. *Submitted*
75. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, **Taylor BS**, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI. Prospective genomic profiling of advanced prostate cancer reveals germline and somatic alterations that may impact clinical decision-making. *Submitted*

76. Oldrini B, Hsieh WY, Erdjument-Bromage H, Codega P, Curiel-Garcia A, Vivanco I, Rohle D, Bielski CM, **Taylor BS**, Tempst P, Squatrito M, Mellinghoff IK. Identification of RAN Binding Protein 6 as EGFR feedback regulatory and candidate tumor suppressor. *Submitted*
77. Gao J, Chang MT, Johnsen HC, Gao SP, Sylvester BE, Sumer SO, Solit DB, Taylor BS, Schultz N, Sander C. Protein structure analysis of somatic mutations in cancer extends clinical actionability. *Submitted*
78. Chang MT and **Taylor BS**. On the impact of rare mutations in cancer. *In revision*
79. Burgess MR, Hwang E, Wandler AM, Firestone AJ, Asthana S, Davis EM, Xu Jin, Akagi K, Le Beau MM, Li Q, Sampath D, **Taylor BS**, Shannon K. Loss of wild-type Kras increases fitness and promotes MAP kinase pathway addition in Kras mutant acute myeloid leukemia. *In revision*
80. Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan V, Kundra R, Abehouse A, Viale A, Cha EK, Bochner BH, Rosenberg JE, Bajorin DF, Schultz N, Berger MF, Iyer G, Al-Ahmadie H, Solit DB, **Taylor BS**. Obligate lesions and diverse evolutionary patterns drive small cell bladder cancer. *In preparation*
81. Soumerai TE, Donoghue M, Bhattarai TS, Chang MT, Charen AS, Zamarin D, Latif A, Cadoo KA, Grishman RN, O'Cearbhaill RE, Bell-McGuinn KM, Tew WP, Konner JA, Troso-Sandoval TA, Hensley ML, Sabbatini P, Spriggs DR, Makker V, Levine DA, Middha S, Murali R, Soslow R, DeLair D, Baselga J, Zehir A, Aghajanian C, Viale A, Berger MF, Solit DB, Hyman H, **Taylor BS**. Identifying actionable mutations in endometrial cancer. *In preparation*

Books and Chapters

1. Sreekumar A, **Taylor BS**, Wang X, Lubman D, Chinnaiyan AM. Humoral Response Profiling Using Protein Microarrays. In *Functional Protein Microarrays in Drug Discovery*, ed. PF. Predki, Taylor & Francis CRC Press, Inc. 2007
2. Rosen N, **Taylor BS**, Baselga J., eds. Cancer Networks, Cold Spring Harbor Laboratory Press, New York. *In preparation*